Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 4/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799706 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29385767 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL1514663 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29406248 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29410226 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL3736523 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29400401 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29754274 | 0.97 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL8248794 | 0.92 | MDM4 (0.49) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL15697341 | 0.90 | CTSB (0.49) | MDM4TP53CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| US-20250090698-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | INDIAN INSTITUTE OF TECH INDORE (IN) | 2025-03-20 | — | — | US | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| CN-116655516-A | Compound for prostate cancer specific fluorescent probe, preparation method and application thereof | 中国医学科学院肿瘤医院深圳医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115925586-A | Preparation method of parent of targeting PSMA and derivative thereof | 青岛蓝谷多肽生物医药科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-114634425-A | Novel synthesis process of PSMA inhibitor | 湖北强耀生物科技有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-110898233-B | Three-modal prostate cancer targeted nanoparticle imaging agent and preparation method thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2022-04-05 | — | — | CN | claimed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026098617-A1 | RADIOPHARMACEUTICAL TARGETING CARBONIC ANHYDRASE IX PROTEIN | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| US-12612343-B2 | PSMA binder and use thereof | Shiya Pharmaceutical, Inc (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-3723815-B1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | UNIV MUENCHEN TECH (DE) | 2022-04-20 | — | — | EP | disclosed |
| CN-114364690-A | Novel radiolabeled CXCR4 targeting compounds for diagnosis and therapy | 省卫生服务机构 | 2022-04-15 | — | — | CN | disclosed |
| CN-110898233-B | Three-modal prostate cancer targeted nanoparticle imaging agent and preparation method thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2022-04-05 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3956346-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | Provincial Health Services Authority (CA) | 2022-02-23 | — | — | EP | disclosed |
| EP-3554559-B1 | METHOD FOR LABELING OF SENSITIVE AND THERMOSENSITIVE TARGETING BIOMOLECULES WITH TECHNETIUM BASED COMPOUNDS | BRACCO IMAGING SPA (IT) | 2022-02-02 | — | — | EP | disclosed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | MDM4 4599/4885TP53 3128/4885ACE 1415/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | MDM4 4874/4885TP53 2182/4885ACE 1725/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM4 3817/4885TP53 1733/4885ACE 4450/4885 |
| US-20250090698-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | KLK3, SPAG5, DNPEP | MDM4 2431/4885TP53 195/4885ACE 1091/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | MDM4 3255/4885TP53 4176/4885ACE 4562/4885 |
| US-12612343-B2 | PSMA binder and use thereof | KLK3, AR, PSMA1 | MDM4 3499/4885TP53 566/4885ACE 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.